A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors

ABSTRACT: This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

DISEASE(S): Uterine Cervical Neoplasms,Breast Carcinoma,Carcinoma,Thymoma,Carcinoma, Basal Cell,Small Cell Lung Cancer,Mesothelioma,Urothelial Carcinoma,Endometrial Neoplasms,Breast Neoplasms,Lung Neoplasms,Squamous Cell Carcinoma Of The Anus,Non-squamous Cell Salivary Gland Carcinoma,Gastric Or Gastroesophageal Junction Adenocarcinoma,Vulvar Neoplasms,Ovarian Cancer,Colorectal Carcinoma,Fallopian Tube Carcinoma,Castration-resistant Prostate Carcinoma,Squamous Cell Carcinoma Of The Head And Neck,Ovarian Carcinoma,Thymic Carcinoma,Gastric Cancer,Basal Cell Carcinoma,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Renal Cell Carcinoma,Non-small Cell Lung Carcinoma,Cholangiocarcinoma,Hepatocellular Carcinoma,Malignant Adnexal Neoplasms,Nasopharyngeal Carcinoma,Cervical Cancer,Melanoma,Small Cell Lung Carcinoma,Vulvar Carcinoma,Solid Tumors With Published Evidence Of Anti-tumor Activity With Anti-pd1/pdl1 And/or Anti-ctla4-directed Therapy,Neuroendocrine Carcinoma,Anus Neoplasms,Carcinoma, Squamous Cell,Squamous Cell Carcinoma Of Head And Neck,Carcinoma, Neuroendocrine,Squamous Cell Carcinoma Of The Penis,Non-small Cell Lung Cancer,Prostate Cancer,Head And Neck Cancer,Mesothelioma, Malignant,Endometrial Carcinoma

PROVIDER: 2272339 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR